Synact Pharma ApS
- Address
- Dronninggaards Alle 136
Sponsor Overview
Specializations
Nephrology and proteinuric kidney disease
Synact Pharma ApS is involved in clinical research for idiopathic membranous nephropathy with severe proteinuria, reflecting an interest in renal conditions marked by persistent loss of protein in the urine and immune-mediated kidney injury.
- Proteinuria reduction
- Idiopathic membranous nephropathy
- Renal inflammation
Its kidney-focused studies address both disease activity and urinary protein excretion as key clinical concerns in nephrology.
Rheumatology and inflammatory arthritis
The sponsor funds research in rheumatoid arthritis, with attention to early disease characterized by active inflammation and the need for effective symptom control in DMARD-naïve participants.
- Rheumatoid arthritis
- Early inflammatory arthritis
- Methotrexate combination treatment
This area places the sponsor within the therapeutic landscape of chronic autoimmune joint disease and anti-inflammatory treatment strategies.
Polymyalgia rheumatica and systemic inflammation
Synact Pharma ApS also supports studies in polymyalgia rheumatica, a condition associated with musculoskeletal pain, stiffness, and inflammatory activity in older adults.
- Polymyalgia rheumatica
- Inflammatory pain syndromes
- Musculoskeletal stiffness
Its research in this field reflects interest in disorders where controlling inflammation is central to improving daily function and disease management.
Immunology and immune-mediated disease
The sponsor’s trial portfolio spans immune-driven conditions affecting the kidneys and musculoskeletal system, indicating a focus on autoimmune disease mechanisms and inflammatory regulation.
- Autoimmune disorders
- Immune-mediated inflammation
- Chronic inflammatory disease
These studies connect immunology with therapeutic development across renal and rheumatic disease areas.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study of Resomelagon in Patients with Idiopathic Membranous Nephropathy and Severe Proteinuria |  Denmark Sweden | Recruiting |
| Efficacy and Safety Evaluation of Oral Resomelagon with Methotrexate in DMARD-Naïve Patients with Early Rheumatoid Arthritis: A Phase II Multicenter Study |  Bulgaria Czechia Denmark Poland Romania | Not Recruiting |
| Efficacy and Safety of Oral AP1189 in Patients with Polymyalgia Rheumatica in Glucocorticoid Remission: A Phase II Randomized, Double-Blind, Placebo-Controlled Trial | Denmark | Not Yet Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 32 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases2 trials322 other sponsors
- 2.Musculoskeletal Diseases1 trial238 other sponsors
Partnered Research Centres
32 centres- Address
- Na Sibeniku 914/1 Nova Ulice, 779 00 Olomouc
- Address
- Ul. Zgierska 249, 91-495 Lodz
- Address
- Plac Szczepanski 3, 31-011 Krakow
- Address
- Nám. Republiky 653, 742 13 Butovice
- Address
- Ul. Dworcowa 5, 58-100 Swidnica
- Address
- Ulitsa Todor Kableshkov 2, 3600 Lom
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Synact Pharma ApS.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.